"10.1371_journal.pone.0034326","plos one","2012-04-16T00:00:00Z","Stephanie Beq; Sandra Rozlan; Sandy Pelletier; Bernard Willems; Julie Bruneau; Jean-Daniel Lelievre; Yves Levy; Naglaa H Shoukry; Rémi Cheynier","Département de Virologie, Institut Pasteur, Paris, France; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Hôpital St-Luc, Montréal, Québec, Canada; Département de microbiologie et immunologie, Université de Montréal, Montréal, Québec, Canada; Département de médecine, Université de Montréal, Montréal, Québec, Canada; Département de médecine familiale, Université de Montréal, Montréal, Québec, Canada; Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier, Immunologie Clinique, INSERM, U955, Université Paris 12, Créteil, France; Inserm U1016, Département Immunologie-Hématologie, Institut Cochin, Paris, France; CNRS, UMR 8104, Paris, France; Faculté de Médecine René Descartes, Université Paris Descartes, UMR-S 8104, Paris, France","Conceived and designed the experiments: RC SB. Performed the experiments: SB SR SP. Analyzed the data: RC NHS SB. Contributed reagents/materials/analysis tools: BW JB JDL YL. Wrote the paper: RC SB.","The authors have the following conflicts: Dr. Beg and Dr. Rozlan are now employees of Cytheris S.A., which is developing recombinant interleukin-7 as an immune enhancer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2012","04","Stephanie Beq","SB",9,TRUE,2,3,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
